Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
New RA drug in view
A new rheumatoid arthritis drug from Sanofi and more good news for MSD on blockbuster Keytruda were highlights among pipeline decisions this week.
Perspective
MSD v PBAC: it's all about the data
It might have been short but MSD's statement on the revised draft report of the post-market review of ezetimibe spoke volumes on how treatment of PBS data can skew conclusions to potentially alarming effect.
Approvals Action
New hope for metabolic disease
Alexion's orphan therapy Kanuma has been approved by the TGA for metabolic disease lysomal acid lipase deficiency.